ArticleJournal of clinical microbiology2019
Evaluation of
Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Lateral-flow device for the diagnosis of invasive aspergillosis: a systematic review and diagnostic meta-analysis.BMC infectious diseases · 2025Pooled it
- Evaluating the Potential of Galactosaminogalactan as a Diagnostic Target for Invasive Aspergillosis.Mycoses · 2025Article
- The Utility of Galactomannan and Polymerase Chain Reaction Assays in Bronchoalveolar Lavage for Diagnosis of Chronic Pulmonary Aspergillosis.Mycopathologia · 2023Article
- Review
- The SSS revolution in fungal diagnostics: speed, simplicity and sensitivity.British medical bulletin · 2023Article
- Diagnosis of Chronic Pulmonary Aspergillosis: Challenges and Limitations Response to "Diagnosis of Chronic Pulmonary Aspergillosis: Which Is the Best Investigation?" and "Diagnosis of Chronic Pulmonary Aspergillosis".The American journal of tropical medicine and hygiene · 2023Article
- Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.Frontiers in immunology · 2023Review
- The Role of Diagnostics-Driven Antifungal Stewardship in the Management of Invasive Fungal Infections: A Systematic Literature Review.Open forum infectious diseases · 2022Review
- Article
- SARS-CoV-2 Associated Immune Dysregulation and COVID-Associated Pulmonary Aspergilliosis (CAPA): A Cautionary Tale.International journal of molecular sciences · 2022Review
- Biosensors and Diagnostics for Fungal Detection.Journal of fungi (Basel, Switzerland) · 2020Review
- Chronic Pulmonary Aspergillosis: Notes for a Clinician in a Resource-Limited Setting Where There Is No Mycologist.Journal of fungi (Basel, Switzerland) · 2020Review
- Invasive pulmonary aspergillosis in the post-COVID-19 era: diagnosis, treatment, and what lies ahead.Therapeutic advances in infectious diseaseReview
- Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.